- Home
- IKNA vs NSPR Comparison
IKNA vs NSPR Comparison
Compare IKNA & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- NSPR
- Stock Information
- Founded
- IKNA 2016
- NSPR 2005
- Country
- IKNA United States
- NSPR United States
- Employees
- IKNA N/A
- NSPR N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- IKNA Health Care
- NSPR Health Care
- Exchange
- IKNA Nasdaq
- NSPR Nasdaq
- Market Cap
- IKNA 63.7M
- NSPR 74.8M
- IPO Year
- IKNA 2021
- NSPR N/A
- Fundamental
- Price
- IKNA $1.43
- NSPR $2.43
- Analyst Decision
- IKNA Buy
- NSPR Strong Buy
- Analyst Count
- IKNA 2
- NSPR 2
- Target Price
- IKNA $13.50
- NSPR $4.50
- AVG Volume (30 Days)
- IKNA 434.6K
- NSPR 85.8K
- Earning Date
- IKNA 07-24-2025
- NSPR 08-05-2025
- Dividend Yield
- IKNA N/A
- NSPR N/A
- EPS Growth
- IKNA N/A
- NSPR N/A
- EPS
- IKNA N/A
- NSPR N/A
- Revenue
- IKNA N/A
- NSPR $7,027,000.00
- Revenue This Year
- IKNA N/A
- NSPR $4.85
- Revenue Next Year
- IKNA N/A
- NSPR $113.47
- P/E Ratio
- IKNA N/A
- NSPR N/A
- Revenue Growth
- IKNA N/A
- NSPR 8.49
- 52 Week Low
- IKNA $0.97
- NSPR $1.99
- 52 Week High
- IKNA $1.94
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- IKNA 59.83
- NSPR 52.46
- Support Level
- IKNA $1.20
- NSPR $2.24
- Resistance Level
- IKNA $1.42
- NSPR $2.55
- Average True Range (ATR)
- IKNA 0.08
- NSPR 0.14
- MACD
- IKNA 0.00
- NSPR 0.02
- Stochastic Oscillator
- IKNA 82.26
- NSPR 59.51
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.